BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the development of an oral dissolvable film (ODF) formulation of Semaglutide, a GLP-1 receptor agonist currently marketed globally under the brand names Ozempic, Rybelsus, and Wegovy.

This initiative marks a significant step in evaluating BioNxt's proprietary thin film drug delivery platform as a non-invasive, user-friendly alternative to injectable and tablet-based GLP-1 therapies. The study is designed to assess the compatibility of Semaglutide with BioNxt's ODF technology and generate early data to inform formulation optimization and intellectual property strategy.

"We believe there is a compelling opportunity to rethink how complex molecules like Semaglutide are delivered," said Hugh Rogers, CEO at BioNxt. "Our oral thin film platform is engineered to improve patient adherence and comfort, and this feasibility study is an important first step in bringing a new delivery option to market."

Semaglutide: A High-Growth Market Segment

Semaglutide is a GLP-1 analog that has rapidly become a blockbuster drug for type 2 diabetes and obesity, with growing use in cardiovascular risk reduction. According to a 2024 report by Data Bridge Market Research, the global GLP‑1 receptor agonist market was valued at USD 24.4 billion in 2023 and is projected to reach approximately USD 156.7 billion by 2030, driven by increasing obesity rates and the rising demand for non‑insulin therapies.

Despite its success, most current Semaglutide formulations still require weekly injections or large daily oral tablets, which can affect patient adherence. A rapidly dissolving oral thin film promises a significant boost in accessibility, convenience, and overall patient experience.

Study Objectives

The feasibility program includes:

• Pre-formulation screening and platform compatibility assessment

• Drug loading and film integrity evaluation for peptide stability

• Generation of early-stage technical data to support patent filings

The feasibility study is currently in the planning phase, with receipt of the Semaglutide active pharmaceutical ingredient (API) anticipated in July. Upon delivery, pre-formulation activities and laboratory-scale formulation trials will be initiated. Subsequent prototype development and characterization are expected to support a provisional patent filing in the third quarter of 2025.